- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03408444
Evaluating Soft Contact Lens Prototypes for Myopia Control
May 13, 2022 updated by: Johnson & Johnson Vision Care, Inc.
This is a multi-site, prospective, randomized, controlled, double-masked, four-arm-parallel-group, dispensing study.
Each subject will be bilaterally fitted with one of four types of test articles and wear contact lenses of the assigned lens type during the entire course of the study.
Test articles will be worn a minimum 8 hours per day and 5 days per week (subjects will be encouraged to wear study contact lenses 10 hours or more per day and 7 days per week) in a daily disposable modality for a minimum of 6 months and up to 1 year for a total of 7 scheduled visits.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
240
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Shanghai, China, 200031
- Fudan University Shanghai EENT Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 12 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
Potential subjects must satisfy all of the following criteria to be enrolled in the study:
- The subject must read (or be read to), understand, and sign the Statement of Information and Assent and receive a fully executed copy of the form.
- The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form.
- Appear able and willing to adhere to the instructions set forth in this clinical protocol.
- Between 7 and 12 years of age (inclusive).
- Have normal eyes (i.e., no ocular medications or infections of any type).
- Distance subjective best-sphere refraction must be between -0.75D and -4.50D (inclusive) in each eye.
- Cylindrical refraction must be 1.00D or less in each eye, by subjective sphero-cylindrical refraction.
- Have sphero-cylindrical best-corrected visual acuity of 20/25 (ie, 0.8 in decimal convention or 0.10 logMAR) or better in each eye.
- Cycloplegic objective sphero-cylindrical refraction (by auto refraction) must be between -0.75D and -4.50D in sphere and is 1.00D or less in cylinder in each eye (based on the average of 5 repeated sphero-cylindrical refraction measures).
The difference in spherical equivalent power between the two eyes must be less than 1.50D (based on the average of 5 repeated sphero-cylindrical refraction measures).
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
- Currently pregnant or lactating.
- Any systemic allergies, infectious disease (e.g., hepatitis, tuberculosis), autoimmune disease (e.g., rheumatoid arthritis), or other systemic diseases (e.g., diabetes), by the parent or legal guardian's report, which are known to interfere with contact lens wear and/or participation in the study.
- Use of systemic medications (e.g., chronic steroid use) that are known to interfere with contact lens wear.
- Any current use of ocular topical medication.
- Any previous or planned ocular or intraocular surgery, including refractive surgery.
- Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
- Participation in any prior myopia control clinical study in the test group.
- Current or recent (within 30 days from enrollment) rigid lens wearers.
- History of orthokeratology treatment or use of other ophthalmic devices (e.g., bifocal, multifocal contact or spectacle lenses) or drugs (e.g., atropine or pirenzepine) for the purpose of controlling myopia progression.
- Any known hypersensitivity or allergic reaction to EyeCept® (or sponsor approved equivalent) Rewetting Drop Solution.
- Relatives of employee of investigational clinic (e.g., Investigator, Coordinator, Technician).
- Any ocular allergies, infections or other ocular abnormalities that are known to interfere with contact lens wear and/or participation in the study. This may include, but not be limited to, aphakia, uveitis, ocular hypertension, glaucoma, severe keratoconjunctivitis sicca, history of recurrent corneal erosions, keratoconus, keratoconus suspect, pellucid marginal degeneration, entropion, ectropion, extrusions, chalazia, and recurrent styes.
- Grade 3 or greater palpebral conjunctival observations or any other grade 2 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, conjunctival injection) on the ISO 11980 classification scale.
- Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar), or any other ocular abnormality that may contraindicate contact lens wear.
- Any central corneal scar
- Any corneal distortion resulting from ocular diseases or previous hard or rigid gas permeable contact lens wear.
- Binocular vision abnormality, intermittent strabismus or strabismus.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: EMO-114
Test Lens 1
|
Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Other Names:
|
|
Experimental: EMO-116
Test Lens 2
|
Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Other Names:
|
|
Experimental: EMO-118
Test Lens 3
|
Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Other Names:
|
|
Active Comparator: EMO-117
Test Lens 4
|
Subjects between the ages of 7 and 12 years old will be bilaterally fitted with one of the four types of test articles and wear lenses of the assigned lens type during the entire course of the study.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Axial Length
Time Frame: 6-month follow-up
|
Axial length (in the unit of mm) was measured by a commercially available device based on the interferometry technique.
|
6-month follow-up
|
|
Spherical Equivalent of Cycloplegic Autorefraction (SECAR)
Time Frame: 6-month follow-up
|
SECAR (in the unit of D) was computed from the spherocylindrical refraction measured by a commercially available autorefractor.
|
6-month follow-up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 27, 2017
Primary Completion (Actual)
May 25, 2019
Study Completion (Actual)
May 25, 2019
Study Registration Dates
First Submitted
January 17, 2018
First Submitted That Met QC Criteria
January 17, 2018
First Posted (Actual)
January 24, 2018
Study Record Updates
Last Update Posted (Actual)
June 8, 2022
Last Update Submitted That Met QC Criteria
May 13, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR-5959
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visual Acuity
-
Mayo ClinicNot yet recruitingVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.Completed
-
Alcon ResearchQueensland University of TechnologyCompleted
-
Alcon ResearchCompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Johnson & Johnson Vision Care, Inc.Completed
Clinical Trials on EMO-114
-
Johnson & Johnson Vision Care, Inc.Completed
-
Johnson & Johnson Vision Care, Inc.CompletedVisual AcuityUnited States
-
Avobis Bio, LLCAlimentiv Inc.AvailablePerianal Fistula Due to Crohn's Disease
-
Rafael NaviaCompletedDepressive and Anxiety DisordersEcuador
-
ORIC PharmaceuticalsCompleted
-
Fusion Pharma LLCData Matrix Solutions; OCT Rus, LLC; Skolkovo Innovation CenterUnknownLeukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myeloid LeukemiaRussian Federation
-
Avobis Bio, LLCAlimentiv Inc.Active, not recruitingCrohn's Disease | Perianal FistulaUnited States
-
Placon TherapeuticsUnknownBreast Neoplasms | Prostatic Neoplasms | Pancreatic Neoplasms | Ovarian NeoplasmsUnited States